# A Study of Low and Standard-dose Ticagrelor After Intervention for ACS Patients

Study · id `cardio:ct-nct04255602` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04255602](<https://clinicaltrials.gov/study/NCT04255602>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT04255602

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 2120 participants.

## Technical summary

Registry record NCT04255602. Randomized; no masking; primary purpose treatment. Start 2020-02-19 (actual); primary completion 2024-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 2120 participants (planned count; ClinicalTrials.gov record NCT04255602, source copy `cardio:ctgov-nct04255602-2023-12-07`, retrieved 2026-10-31)
- Started: 2020-02-19 (actual) (ClinicalTrials.gov record NCT04255602, source copy `cardio:ctgov-nct04255602-2023-12-07`, retrieved 2026-10-31)
- Primary completion: 2024-12-31 (anticipated) (ClinicalTrials.gov record NCT04255602, source copy `cardio:ctgov-nct04255602-2023-12-07`, retrieved 2026-10-31)
- Completion: 2024-12-31 (anticipated) (ClinicalTrials.gov record NCT04255602, source copy `cardio:ctgov-nct04255602-2023-12-07`, retrieved 2026-10-31)
- Countries: China (ClinicalTrials.gov record NCT04255602, source copy `cardio:ctgov-nct04255602-2023-12-07`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04255602-2023-12-07`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Study of Low and Standard-dose Ticagrelor After Intervention for ACS Patients
- Acronym: TIGER
- Condition: Acute Coronary Syndrome
- Condition: Coronary Stent Implantation
- Intervention (Drug): Ticagrelor 60mg
- Intervention (Drug): Ticagrelor 90mg
- Lead sponsor: Shanghai Tong Ren Hospital
- Lead sponsor class: OTHER
- Collaborator: Shanghai Jiao Tong University School of Medicine
- Collaborator class: OTHER
- Collaborator: Fudan University
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Acute coronary syndrome (`cardio:acute-coronary-syndrome`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Ticagrelor (`cardio:ticagrelor`)
- Registry intervention is a member of this class by a sourced record link: P2Y12 inhibitors (drug class) (`cardio:p2y12-inhibitors`)
- Registry lists this organization as a collaborator: Shanghai Jiao Tong University School of Medicine (`cardio:org-shanghai-jiao-tong-university-school-of-medicine`)
- Registry lists this organization as a collaborator: Fudan University (`cardio:org-fudan-university`)

## Provenance

Content hash: 4e6aee11f7d2ce677a8ea4e47a2975e5f7df59cd86638b4a62d0a63754ffb3c2
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
